Bengt Edvardsson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bengt Edvardsson has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Staffan Persson
Department of Neurology, Faculty of Medicine, Skane University Hospital, Lund, Sweden
6 shared publicationsS. Persson
Department of Neurology, Faculty of Medicine, Lund University Hospital, Lund, Sweden
2 shared publicationsStaffan Persson
1 shared publication- Staffan Persson
Department of Neurology, Faculty of Medicine, Skane University Hospital, S-221 85 Lund, Sweden
1 shared publication
Latest Publications
- Open Access
- 26 February 2015
- Published by Springer Nature in SpringerPlus
- Vol. 4 (1) , 1-4
Venlafaxine as single therapy associated with hypertensive encephalopathy
Hypertensive encephalopathy with the clinicoradiological entity posterior reversible encephalopathy syndrome in the setting of venlafaxine as single therapy has not been reported earlier. A 46-year-old man developed hypertensive encephalopathy associated with venlafaxine as single therapy. Magnetic resonance imaging of the brain, pre and post gadolinium, carried out on day 2, displayed an increased T2 signal in the cortex on both the T2 and FLAIR images throughout the frontal and temporal lobes and in the cerebellum. Venlafaxine therapy was stopped. The patient gradually improved and he became seizure free and the blood pressure successively became normal. A magnetic resonance imaging after six weeks displayed marked regression of the abnormalities. On follow-up after 3 months, his blood pressure had been normal and he had not had any symptoms. The prescribed antiepileptic drug was discontinued as well as antihypertensive treatment. He had not experienced any new symptoms at follow-up after one year. The patient in this report had hypertensive encephalopathy associated with venlafaxine therapy. The imaging findings are compatible with hypertensive encephalopathy/posterior reversible encephalopathy syndrome. Venlafaxine is a drug used very frequently. Venlafaxine may infrequently induce hypertensive crisis. Hypertensive encephalopathy may rarely occur in the setting of venlafaxine as single therapy even in low to moderate doses. Patients on venlafaxine should have regular monitoring of blood pressure. Knowledge of the side effects is vital. Venlafaxine must be discontinued if significant hypertension persists.
- 26 February 2015
- Published by Springer Nature in SpringerPlus
- Vol. 4 (1) , 1-4
Open AccessVenlafaxine as single therapy associated with hypertensive encephalopathy
Hypertensive encephalopathy with the clinicoradiological entity posterior reversible encephalopathy syndrome in the setting of venlafaxine as single therapy has not been reported earlier. A 46-year-old man developed hypertensive encephalopathy associated with venlafaxine as single therapy. Magnetic resonance imaging of the brain, pre and post gadolinium, carried out on day 2, displayed an increased T2 signal in the cortex on both the T2 and FLAIR images throughout the frontal and temporal lobes and in the cerebellum. Venlafaxine therapy was stopped. The patient gradually improved and he became seizure free and the blood pressure successively became normal. A magnetic resonance imaging after six weeks displayed marked regression of the abnormalities. On follow-up after 3 months, his blood pressure had been normal and he had not had any symptoms. The prescribed antiepileptic drug was discontinued as well as antihypertensive treatment. He had not experienced any new symptoms at follow-up after one year. The patient in this report had hypertensive encephalopathy associated with venlafaxine therapy. The imaging findings are compatible with hypertensive encephalopathy/posterior reversible encephalopathy syndrome. Venlafaxine is a drug used very frequently. Venlafaxine may infrequently induce hypertensive crisis. Hypertensive encephalopathy may rarely occur in the setting of venlafaxine as single therapy even in low to moderate doses. Patients on venlafaxine should have regular monitoring of blood pressure. Knowledge of the side effects is vital. Venlafaxine must be discontinued if significant hypertension persists.
- 1 February 2015
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 115 (4) , 741-742
Hypertensive encephalopathy associated with obstructive sleep apnoea syndrome
- 1 February 2015
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 115 (4) , 741-742
Hypertensive encephalopathy associated with obstructive sleep apnoea syndrome
- Open Access
- 20 December 2014
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 8 (1) , 451
Cluster headache associated with a clinically non-functioning pituitary adenoma: a case report
Cluster headache belongs to a group of primary headache entities: the trigeminal autonomic cephalalgias. Cluster headache is the most common variant. The headache is usually severe and it is also associated with autonomic symptoms. Secondary causes of cluster headache have been reported, such as intracranial artery aneurysms and tumors. The question of when to carry out neuroimaging in patients with cluster headache is yet unsettled. To the best of the author's knowledge, cluster headache associated with a clinically non-functioning pituitary adenoma (chromophobe adenoma) has not been described. This case report describes the case of a man with cluster headache where the evaluation showed a clinically non-functioning pituitary adenoma.
- 20 December 2014
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 8 (1) , 451
Open AccessCluster headache associated with a clinically non-functioning pituitary adenoma: a case report
Cluster headache belongs to a group of primary headache entities: the trigeminal autonomic cephalalgias. Cluster headache is the most common variant. The headache is usually severe and it is also associated with autonomic symptoms. Secondary causes of cluster headache have been reported, such as intracranial artery aneurysms and tumors. The question of when to carry out neuroimaging in patients with cluster headache is yet unsettled. To the best of the author's knowledge, cluster headache associated with a clinically non-functioning pituitary adenoma (chromophobe adenoma) has not been described. This case report describes the case of a man with cluster headache where the evaluation showed a clinically non-functioning pituitary adenoma.
- Open Access
- 16 December 2014
- Published by Springer Nature in SpringerPlus
- Vol. 3 (1) , 741
Hypertensive encephalopathy and cerebral infarction
Hypertensive encephalopathy is one cause of posterior reversible encephalopathy syndrome. Hypertensive encephalopathy and cerebral infarction have only been reported in a few individual case reports. A 51-year-old woman presented with hypertensive encephalopathy. T2-weighted images from magnetic resonance imaging showed hyperintense lesions in both occipital and parietal lobes. Diffusion-weighted imaging showed that this represented cytotoxic oedema and perfusion magnetic resonance imaging revealed reduced blood volume and flow. The magnetic resonance imaging was repeated 5 months later and subtotal regression of theT2-hyperintensity had occurred. However, small bilateral infarcts were seen on T1-weighted images. Perfusion magnetic resonance imaging presented reduced blood volume and flow on the right side. The patient in this report had posterior reversible encephalopathy syndrome caused by hypertensive encephalopathy. Magnetic resonance imaging of the brain showed bilateral cytotoxic oedema that partially resolved and resulted in small infarcts. The imaging findings are compatible with posterior reversible encephalopathy syndrome with subtotal resolution and infarct evolution. The case report suggests that the presence of hypertensive encephalopathy and posterior reversible encephalopathy syndrome should alert clinicians and lead to prompt treatment in order to prevent cerebral damage.
- 16 December 2014
- Published by Springer Nature in SpringerPlus
- Vol. 3 (1) , 741
Open AccessHypertensive encephalopathy and cerebral infarction
Hypertensive encephalopathy is one cause of posterior reversible encephalopathy syndrome. Hypertensive encephalopathy and cerebral infarction have only been reported in a few individual case reports. A 51-year-old woman presented with hypertensive encephalopathy. T2-weighted images from magnetic resonance imaging showed hyperintense lesions in both occipital and parietal lobes. Diffusion-weighted imaging showed that this represented cytotoxic oedema and perfusion magnetic resonance imaging revealed reduced blood volume and flow. The magnetic resonance imaging was repeated 5 months later and subtotal regression of theT2-hyperintensity had occurred. However, small bilateral infarcts were seen on T1-weighted images. Perfusion magnetic resonance imaging presented reduced blood volume and flow on the right side. The patient in this report had posterior reversible encephalopathy syndrome caused by hypertensive encephalopathy. Magnetic resonance imaging of the brain showed bilateral cytotoxic oedema that partially resolved and resulted in small infarcts. The imaging findings are compatible with posterior reversible encephalopathy syndrome with subtotal resolution and infarct evolution. The case report suggests that the presence of hypertensive encephalopathy and posterior reversible encephalopathy syndrome should alert clinicians and lead to prompt treatment in order to prevent cerebral damage.
- 16 October 2014
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 115 (3) , 457-458
Hypertensive encephalopathy associated with anabolic–androgenic steroids used for bodybuilding
- 16 October 2014
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 115 (3) , 457-458
Hypertensive encephalopathy associated with anabolic–androgenic steroids used for bodybuilding
- Open Access
- 3 February 2014
- Published by Springer Nature in SpringerPlus
- Vol. 3 (1) , 64
Symptomatic cluster headache: a review of 63 cases
Cluster headache is a primary headache by definition not caused by any known underlying structural pathology. Symptomatic cases have been described, for example tumours, dissections and infections, but a causal relationship between the underlying lesion and the headache is difficult to determine in many cases. The proper diagnostic evaluation of cluster headache is an issue unresolved. The literature has been reviewed for symptomatic cluster headache or cluster headache-like cases in which causality was likely. The review also attempted to identify clinical predictors of underlying lesions in order to formulate guidelines for neuroimaging. Sixty-three cluster headache or
- 3 February 2014
- Published by Springer Nature in SpringerPlus
- Vol. 3 (1) , 64
Open AccessSymptomatic cluster headache: a review of 63 cases
Cluster headache is a primary headache by definition not caused by any known underlying structural pathology. Symptomatic cases have been described, for example tumours, dissections and infections, but a causal relationship between the underlying lesion and the headache is difficult to determine in many cases. The proper diagnostic evaluation of cluster headache is an issue unresolved. The literature has been reviewed for symptomatic cluster headache or cluster headache-like cases in which causality was likely. The review also attempted to identify clinical predictors of underlying lesions in order to formulate guidelines for neuroimaging. Sixty-three cluster headache or
- 2 January 2014
- Vol. 110 (46) , 2054-7
[Cluster headaches can be associated with underlying disease].
- Open Access
- 5 October 2013
- Published by Springer Nature in SpringerPlus
- Vol. 2 (1) , 509
Cluster headache associated with acute maxillary sinusitis
Cluster headache is a primary headache by definition not caused by any known underlying structural pathology. However, symptomatic cases have been described, for example tumours, particularly pituitary adenomas, malformations, and infections/inflammations. The evaluation of cluster headache is an issue unresolved. I present a case of a 24-year-old patient who presented with a 4-week history of side-locked attacks of pain located in the left orbit. He satisfied the revised International Classification of Headache Disorders criteria for cluster headache. His medical and family histories were unremarkable. There was no history of headache. A diagnosis of cluster headache was made. The patient responded to symptomatic treatment. Low-dose computer tomography scan after 2 weeks displayed a left-sided acute maxillary sinusitis. The headache attacks resolved completely after treatment with antibiotics and sinus puncture. Although I cannot exclude an unintentional comorbidity, in my opinion, the co-occurrence of an acute maxillary sinusitis with unilateral headache, in a hitherto headache-free man, points toward the fact that in this case the cluster headache was caused or triggered by the sinusitis. The headache attacks resolved completely after the treatment and the patient also remained headache free at the follow-up. The response of the headache to sumatriptan and other typical cluster headache medications does not exclude a secondary form. Symptomatic cluster headaches responsive to this therapy have been described. Associated cranial lesions such as infections have been reported in cluster headache patients and the attacks may be clinically indistinguishable from the primary form. Neuroimaging, preferably contrast-enhanced magnetic resonance imaging including sinuses should always be considered in patients with cluster headache despite normal neurological examination. Acute maxillary sinusitis can present as cluster headache.
- 5 October 2013
- Published by Springer Nature in SpringerPlus
- Vol. 2 (1) , 509
Open AccessCluster headache associated with acute maxillary sinusitis
Cluster headache is a primary headache by definition not caused by any known underlying structural pathology. However, symptomatic cases have been described, for example tumours, particularly pituitary adenomas, malformations, and infections/inflammations. The evaluation of cluster headache is an issue unresolved. I present a case of a 24-year-old patient who presented with a 4-week history of side-locked attacks of pain located in the left orbit. He satisfied the revised International Classification of Headache Disorders criteria for cluster headache. His medical and family histories were unremarkable. There was no history of headache. A diagnosis of cluster headache was made. The patient responded to symptomatic treatment. Low-dose computer tomography scan after 2 weeks displayed a left-sided acute maxillary sinusitis. The headache attacks resolved completely after treatment with antibiotics and sinus puncture. Although I cannot exclude an unintentional comorbidity, in my opinion, the co-occurrence of an acute maxillary sinusitis with unilateral headache, in a hitherto headache-free man, points toward the fact that in this case the cluster headache was caused or triggered by the sinusitis. The headache attacks resolved completely after the treatment and the patient also remained headache free at the follow-up. The response of the headache to sumatriptan and other typical cluster headache medications does not exclude a secondary form. Symptomatic cluster headaches responsive to this therapy have been described. Associated cranial lesions such as infections have been reported in cluster headache patients and the attacks may be clinically indistinguishable from the primary form. Neuroimaging, preferably contrast-enhanced magnetic resonance imaging including sinuses should always be considered in patients with cluster headache despite normal neurological examination. Acute maxillary sinusitis can present as cluster headache.
- Open Access
- 22 September 2013
- Published by Springer Nature in SpringerPlus
- Vol. 2 (1) , 479
Atenolol in the prophylaxis of chronic migraine: a 3-month open-label study
Chronic migraine (CM) is a type of chronic daily headache. CM presents a challenge to primary care physicians and neurologists. Any new treatment showing efficiency would therefore be of great importance. Atenolol together with other beta-blockers is a first-line choice in episodic migraine prophylaxis. Clinical findings support the efficacy of atenolol in doses of 50 to 200 mg/day. Here I present an open-label study the aim of which is to evaluate the efficacy and tolerability of atenolol (50 mg o.d) for the prevention of CM. 19 patients affected by CM were studied. Following a one-month run-in period, the patients took atenolol for 3 months. Mean numbers of headache days per month were reduced from 20.1 ± 2.4 during the run-in period to 7.8 ± 6.1 by month 1.5 and to 7.1 ± 5.7 by the 3rd month of treatment (p < 0.0003). There was a significant difference between 1.5 months and the 3rd month (p < 0.006). The severity of attacks was reduced from a mean 2.3 ± 0.6 to 1.4 ± 1.1 (p < 0.010) at 1.5 months. In this, there was no difference between 1.5 months and the 3rd month. In 5 (29%) of the17 patients who completed the study, CM was totally gone during the 3rd month of treatment. No patient was totally unresponsive to the drug. Among the patients who completed the study, the treatment was well tolerated and the compliance was good. Atenolol seems to be a safe and effective treatment for CM. Controlled trials are needed to confirm the observed results.
- 22 September 2013
- Published by Springer Nature in SpringerPlus
- Vol. 2 (1) , 479
Open AccessAtenolol in the prophylaxis of chronic migraine: a 3-month open-label study
Chronic migraine (CM) is a type of chronic daily headache. CM presents a challenge to primary care physicians and neurologists. Any new treatment showing efficiency would therefore be of great importance. Atenolol together with other beta-blockers is a first-line choice in episodic migraine prophylaxis. Clinical findings support the efficacy of atenolol in doses of 50 to 200 mg/day. Here I present an open-label study the aim of which is to evaluate the efficacy and tolerability of atenolol (50 mg o.d) for the prevention of CM. 19 patients affected by CM were studied. Following a one-month run-in period, the patients took atenolol for 3 months. Mean numbers of headache days per month were reduced from 20.1 ± 2.4 during the run-in period to 7.8 ± 6.1 by month 1.5 and to 7.1 ± 5.7 by the 3rd month of treatment (p < 0.0003). There was a significant difference between 1.5 months and the 3rd month (p < 0.006). The severity of attacks was reduced from a mean 2.3 ± 0.6 to 1.4 ± 1.1 (p < 0.010) at 1.5 months. In this, there was no difference between 1.5 months and the 3rd month. In 5 (29%) of the17 patients who completed the study, CM was totally gone during the 3rd month of treatment. No patient was totally unresponsive to the drug. Among the patients who completed the study, the treatment was well tolerated and the compliance was good. Atenolol seems to be a safe and effective treatment for CM. Controlled trials are needed to confirm the observed results.
- 5 February 2013
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 113 (4) , 535-536
Cluster headache and acute maxillary sinusitis
- 5 February 2013
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 113 (4) , 535-536
Cluster headache and acute maxillary sinusitis